methylnaltrexone (relistor) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Methylnaltrexone, is a peripherally acting μ-opioid receptor antagonist that acts on the gastrointestinal tract to inhibit the opioid-induced decrease in gastric motility and transit time. It is used to treat opiate-induced constipation in adults with chronic non-cancer pain and in adults with advanced illness who are receiving palliative care.   NCATS

Chemistry

  • SMILES: C[N+]1(CC2CC2)CC[C@]34[C@H]5Oc6c(O)ccc(C[C@@H]1[C@]3(O)CCC5=O)c46
  • InChIKey: JVLBPIPGETUEET-GAAHOAFPSA-O
  • Mol. Mass: 356.44
  • ALogP: 1.67
  • ChEMBL Molecules:
    methylnaltrexone  
    methylnaltrexone bromide  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$4.1710 - $129.1190

Australia

$24.9492 - $24.9503
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinanium-6-one | (5alpha)-17-(cyclopropylmethyl)-3,14-dihydroxy-17-methyl-4,5-epoxymorphinan-17-ium-6-one | methylnaltrexone | methylnaltrexone bromide | methyl-naltrexone hydrobromide | methylnaltrexonium | mntx | morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, (5alpha)- | morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, bromide, (5alpha,17r)- | morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, (5alpha)- | mrz-2663 | mrz 2663br | mrz-2663br | naltrexone mb | naltrexone methobromide | naltrexone methylbromide | naltrexonium methiodide | n-methylnaltrexone bromide | quaternary ammonium naltrexone | relistor

Organizations (31)

Research & Development (28)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (29)

Approved Indications (1)


 

Constipation

Experimental Indications - Clinical Trial Phases 1-4 (29)


 

Adult (Phase 1)

Constipation ()

Coronary Artery Disease (Phase 4)

Enteral Nutrition (Phase 3)

Esophageal Diseases (Phase 4)

Gastroparesis (Phase 2)

General Surgery (Phase 3)

Healthy Volunteers (Phase 2)

Ileus (Phase 3)

Intestinal Diseases (Phase 2)

Intestinal Obstruction (Phase 1)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Methadone (Phase 1)

Morphine (Phase 4)

Naltrexone (Phase 4)

Neoplasms (Phase 2)

Opioid-Induced Constipation (Phase 4)

Opioid-Related Disorders (Phase 2)

Pancreatic Neoplasms (Phase 3)

Pancreatitis (Phase 2/Phase 3)

Pharyngeal Diseases (Phase 4)

Postoperative Complications (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 4)

ST Elevation Myocardial Infarction (Phase 4)

Stomach Diseases (Phase 4)

Swallows (Phase 4)

Terminally Ill (Phase 3)

Ticagrelor (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 68
  • # of Trial Organizations: 28

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue